Sean D. Sullivan, PhD

A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.

Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.

Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.

We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.